ATS Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATS research report →
Range $34 – $34
Price Chart
About the company
ATS Corporation is a global provider of comprehensive automation solutions, specializing in the entire lifecycle of automated manufacturing and assembly systems. From initial planning, design, and engineering through to building, commissioning, and ongoing servicing, the company supports clients worldwide. Their extensive offerings include a wide array of automation products and advanced test solutions.
- CEO
- Douglas William Wright
- IPO
- 2009
- Employees
- 7,000
- HQ
- Cambridge, ON, CA
Get TickerSpark's AI analysis on ATS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.58B
- P/E
- 260.98
- Fwd P/E
- 13.50
- PEG
- 1.47
- P/S
- 0.84
- P/B
- 1.41
- EV/EBITDA
- 11.71
- Div Yield
- 0.00%
- Gross Margin
- 27.12%
- Op Margin
- 5.70%
- Net Margin
- 0.30%
- ROE
- 0.48%
- ROIC
- 2.05%
Latest fiscal year · YoY change
- Revenue
- $2.97B+17.4%
- Gross Profit
- $850.87M+31.6%
- Op Income
- $221.91M
- Net Income
- $71.64M+355.4%
- EPS
- $0.73+351.7%
- OCF Growth
- +1639.9%
- FCF Growth
- +811.1%
- 52W High
- $35.82
- 52W Low
- $16.44
- 50D MA
- $18.34
- 200D MA
- $25.82
- Beta
- 1.18
- RSI (14)
- 37
- Avg Volume
- 257.62K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ATS delivered strong Q2 bookings and record life sciences backlog, but tariff-related packaging delays and weaker mix pushed out full-year revenue and margin expansion expectations.· November 4, 2026
- Order bookings were $827 million, up 12.7% year over year, and backlog ended at about $2 billion.
- Life sciences backlog hit a record $1.2 billion, with radiopharma a standout and broader diversification in med device and pharma applications.
- Q2 revenue was $666 million and adjusted EPS was $0.27; adjusted earnings from operations were $57.4 million with an 8.6% margin, down from 10.9% last year.
- Management cut its prior full-year outlook for modest revenue growth and margin expansion because packaging orders were delayed by tariffs and revenue conversion takes time.
- The company expects Q3 revenue of $640 million to $680 million and remains focused on a $65 million to $75 million annualized net fixed-cost savings program.
Q2 revenue was $666 million, in line with guidance, and adjusted EPS was $0.27. Order bookings were $827 million, up 12.7% year over year, and the trailing 12-month book-to-bill was 1.05x. Adjusted earnings from operations were $57.4 million, down 27.4% from last year, with an 8.6% margin versus 10.9% a year ago. Gross margin was 28.6%, down 131 basis points year over year. Backlog ended at approximately $2 billion, including $1.2 billion in life sciences. For Q3, management guided revenue to $640 million to $680 million. For fiscal 2027, CapEx and intangible investment is expected to be $60 million to $80 million, and the company now expects to operate moderately above its 2x to 3x net debt to adjusted EBITDA target range for the rest of the year absent major acquisitions or portfolio actions.
Douglas William Wright said the quarter showed strong end-market demand, especially in life sciences, where backlog reached an all-time high and radiopharma remained a major growth area. He emphasized that the tariff impact was concentrated in packaging equipment, not life sciences, and said the late-October tariff changes should help customers resume capital spending over time. His tone was confident but measured, repeatedly framing the delays as temporary while stressing that ATS is reallocating capital toward higher-return segments and investing behind growth areas like radiopharma and nuclear.
Anne Cybulski said ATS no longer expects to achieve its prior full-year goals for modest revenue growth and margin expansion because of order delays, execution timing, and lower revenue/mix in the near term. She outlined the fixed cost transformation program as a net $65 million to $75 million annualized savings opportunity, roughly 250 basis points of margin expansion from a 10% base, with benefits building over the next 15 months. She also reported Q2 operating cash flow of $81 million versus $28 million last year, working capital at 13.4% of revenue, restructuring costs of $21.3 million, and share repurchases of about 2.2 million shares for $61 million; net debt to adjusted EBITDA was 3.1x, or 3.0x excluding the buyback.
Analysts pressed on how much of the booking weakness was caused by Section 38 tariffs and when delayed packaging orders might convert; management said the issue was concentrated in packaging systems, that some Q2 orders simply did not book because customers were waiting, and that the tariff rollback should help, though they would not quantify the timing. Questions also focused on whether fixed-cost transformation savings would be enough to support the 15% margin target without stronger revenue growth; management said the program is designed to deliver savings regardless of top-line growth, with roughly half of the benefit coming from COGS and half from SG&A. On life sciences, management said backlog conversion will take time because many projects are large, multi-quarter factory builds, but they expect that pipeline strength to translate into better revenue in coming quarters.
The call showed strong demand in ATS’s most attractive end markets, with record life sciences backlog, a healthy book-to-bill, and improving diversification beyond radiopharma into med device and other pharma applications. Management also sounded confident that tariff-related delays are temporary and that the fixed cost program, aftermarket focus, and growth investments in nuclear and radiopharma can support better margins over time.
Near-term revenue and margin upside were pushed out because some packaging orders were delayed by tariffs and because many life sciences projects are long-cycle and will not convert quickly. Management also acknowledged margin pressure over the next several months, weaker non-life-sciences activity in areas like food and beverage, and higher leverage than its target range for the rest of fiscal 2027 absent acquisitions or portfolio actions.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.4%
- Shares Outstanding
- 95.92M
- Float Shares
- 95.36M
of shares held by institutions
146 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mason Capital Management LLC | 16.40M | 0 |
| Royal Bank Of Canada | 7.88M | ▲ 119.58K |
| Edgepoint Investment Group Inc. | 7.00M | ▼ 163.53K |
| Beutel, Goodman & Co Ltd. | 6.25M | ▲ 1.45M |
| Turtle Creek Asset Management Inc. | 5.45M | ▲ 2.36M |
| Vanguard Group Inc | 3.40M | ▲ 55.73K |
| Fmr LLC | 2.68M | ▼ 225.40K |
| Fairfax Financial Holdings Ltd/ Can | 2.49M | 0 |
| Vanguard Capital Management LLC | 2.37M | ▼ 26.06K |
| Jupiter Topco LLC | 2.32M | ▲ 2.32M |
| Janus Henderson Group Ltd. | 2.30M | ▲ 1.44M |
| Scheer, Rowlett & Associates Investment Management Ltd. | 2.07M | ▲ 898.09K |
Held by 16 ETFs
Biggest fund positions in ATS by dollar value.
Our ATS coverage
Recent articles, reports, and earnings notes.
No research on ATS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATS report →The New York Stock Exchange Will Soon Use Avalanche for Tokenized Stocks. Is the Coin a Screaming Buy Right Now?
fool.com · Nov 17
New Strong Sell Stocks for November 16th
zacks.com · Nov 16
tZERO Receives CFTC Approval to Operate Regulated Derivatives Exchange and Achieves First Earn-Out Milestone in Proposed FG Imperii Merger
gurufocus.com · Nov 12
ATS to Participate in the Scotiabank Transportation & Industrials Conference
businesswire.com · Nov 11
ATS to Participate in the Baird 2026 Global Industrial Conference
businesswire.com · Nov 9
What ATS (ATS) Said on Its Q2 Earnings Call
marketbeat.com · Nov 5
ATS Corporation (ATS:CA) Q2 2027 Earnings Call Transcript
seekingalpha.com · Nov 4
ATS (ATS) Misses Q2 Earnings and Revenue Estimates
zacks.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.